Physician profile
Larry Everhart
NPI 1144275181
$687.11
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269 · 2020: $222 · 2021: $196.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $161.04 | 2019-2021 | |
| Redhill Biopharma INC. | $102.10 | 2020-2021 | |
| Currax Pharmaceuticals LLC | $91.16 | 2020-2021 | |
| Novo Nordisk INC | $60.67 | 2019 | |
| Merck Sharp & Dohme LLC | $51.32 | 2019-2021 | |
| Ibsa Pharma INC. | $41.88 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $34.58 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $28.87 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $22.97 | 2019 | |
| Romark Laboratories, Lc | $20.77 | 2019 | |
| Eisai INC. | $18.29 | 2020 | |
| Pfizer INC. | $15.60 | 2019 | |
| Endo Pharmaceuticals INC. | $15.04 | 2021 | |
| Lupin INC. | $11.67 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.15 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Everhart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.